Stem Cell Sciences goes US
Wednesday, 04 March, 2009
Technology company Stem Cell Sciences (SCS) is to be sold to Delaware’s StemCells Inc for close to US$5 million.
SCS, which has a research laboratory in Melbourne and is headquartered in Cambridge in the UK, has an impressive portfolio of IP based around technologies for stem cell research including cell-based assays, gene delivery vehicles, cell media and methodologies.
In a statement, the companies said it was expected that SCS’s 20 full-time staff will be retained if the deal goes ahead. Agreement has already been received from 30 per cent of SCS shareholders.
An EGM to vote on the deal will be held in London on 27 March.
How does the brain evaluate rewards?
Neuroscientists have shown how nerve cells in the amygdala not only encode the probability and...
Breakthrough drug prevents long COVID symptoms in mice
Mice treated with the antiviral compound were protected from long-term brain and lung dysfunction...
Antibiotics hinder vaccine response in infants
Infants who received antibiotics in the first few weeks of life had significantly lower levels of...
